SA Government, via BioSA, funds $1 million IP initiative
12 April, 2012 by AusBiotechThe Government of South Australia has announced it will fund a new $1 million initiative over three years to help South Australia’s three main universities seek patent protection for their intellectual property (IP).
QRxPharma completes trials of MoxDuo CR
11 April, 2012 by Dylan Bushell-EmblingQRxPharma (ASX:QRX) has completed two phase 1 trials of its MoxDuo CR dual-opioid tablets, and revealed some positive pharmacokinetic results.
Sirtex Medical Q3 dose sales grow 34%
11 April, 2012 by Dylan Bushell-EmblingNSW-based biotech Sirtex Medical (ASX:SRX) said Q3 dose sales of its SIR-Spheres microspheres liver cancer treatment a record grew 34% year-on-year.
Brain tumour surgery aid gets orphan drug status
11 April, 2012 by Dylan Bushell-EmblingGliolan, a drug licensed to Melbourne's STA which has the ability to make brain tumours glow red during neurosurgery, has been granted orphan drug status by the TGA.
New institute to lead climate change research
10 April, 2012 by AusBiotechLast week's opening of the Hawkesbury Institute for the Environment at the University of Western Sydney provides Australia with a world-class research institute to tackle the impacts of climate change.
Alchemia partner applies to sell fondaparinux in EU
10 April, 2012 by Dylan Bushell-EmblingDr Reddy's Laboratories has submitted an EU marketing authorisation application covering partner Alchemia's (ASX:ACL) fondaparinux anticoagulant.
Clean Technology Investment Programs open
05 April, 2012 by AusBiotechAusIndustry invites those interested in the new Clean Technology Investment Programs to attend an information session to learn about the programs and how to apply.
Phosphagenics signs Indian skincare licensing deal
05 April, 2012 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) has signed a deal to license two anti-ageing products formulated for the Indian market to Intas Pharmaceuticals.
Clinuvel set to accelerate phase III study of Scenesse
05 April, 2012 by Dylan Bushell-EmblingClunivel has reached an in-principle agreement with the US Food and Drug Administration to accelerate the phase III trials of Scenesse for the treatment of erythropoietic protoporphyria (EPP).
PolyNovo commences wound treatment trial
05 April, 2012 by Dylan Bushell-EmblingCalzada (ASX:CZD) unit PolyNovo will soon trial its BTM technology as an implant to treat major burns and other full thickness wounds requiring a skin graft.
Changes to IP laws explained
02 April, 2012 by AusBiotechHow the changes in the 'Raising the Bar' Bill to intellectual property legislation will affect life science companies.
Early data show Bionomics' BNC105 effective against tumours
02 April, 2012 by Dylan Bushell-EmblingPreclinical data shows Bionomics' (ASX:BNO) BNC105 compound can be effective in treating platinum-resistant ovarian cancer tumours.
IQnovate to move to ASX
02 April, 2012 by Dylan Bushell-EmblingContract medical company IQnovate (NSX:IQN) will delist from the NSX and move its public share listing to the ASX.
Merged drug developer nears ASX listing
02 April, 2012 by Dylan Bushell-EmblingBioxyne (ASX:BSN), created from the merger of Hunter Immunology and Probiomics (ASX:PCC), is scheduled to list on the ASX in April.
Pharmaxis signs EU distribution deal for Bronchitol
30 March, 2012 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) has signed a three-year deal with Aravo Healthcare covering distribution of its cystic fibrosis treatment across Europe.
